25 XP   0   0   10

Avalo Therapeutics Inc
Buy, Hold or Sell?

Let's analyse Avalo Therapeutics Inc together

PenkeI guess you are interested in Avalo Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Avalo Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Avalo Therapeutics Inc

I send you an email if I find something interesting about Avalo Therapeutics Inc.

Quick analysis of Avalo Therapeutics Inc (30 sec.)










What can you expect buying and holding a share of Avalo Therapeutics Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
5.6%

What is your share worth?

Current worth
$9.11
Expected worth in 1 year
$31.84
How sure are you?
38.9%

+ What do you gain per year?

Total Gains per Share
$22.73
Return On Investment
166.9%

For what price can you sell your share?

Current Price per Share
$13.62
Expected price per share
$4.35 - $22.68
How sure are you?
50%

1. Valuation of Avalo Therapeutics Inc (5 min.)




Live pricePrice per Share (EOD)

$13.62

Intrinsic Value Per Share

$-206.64 - $-241.05

Total Value Per Share

$-197.53 - $-231.94

2. Growth of Avalo Therapeutics Inc (5 min.)




Is Avalo Therapeutics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$7.3m-$3.1m$5.3m243.2%

How much money is Avalo Therapeutics Inc making?

Current yearPrevious yearGrowGrow %
Making money-$7.8m-$10.4m$2.5m32.1%
Net Profit Margin-1,753.9%-1,052.7%--

How much money comes from the company's main activities?

3. Financial Health of Avalo Therapeutics Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#720 / 1019

Most Revenue
#559 / 1019

Most Profit
#509 / 1019

Most Efficient
#851 / 1019

What can you expect buying and holding a share of Avalo Therapeutics Inc? (5 min.)

Welcome investor! Avalo Therapeutics Inc's management wants to use your money to grow the business. In return you get a share of Avalo Therapeutics Inc.

What can you expect buying and holding a share of Avalo Therapeutics Inc?

First you should know what it really means to hold a share of Avalo Therapeutics Inc. And how you can make/lose money.

Speculation

The Price per Share of Avalo Therapeutics Inc is $13.62. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Avalo Therapeutics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Avalo Therapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $9.11. Based on the TTM, the Book Value Change Per Share is $5.68 per quarter. Based on the YOY, the Book Value Change Per Share is $-4.01 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Avalo Therapeutics Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-10.19-74.8%-9.84-72.2%-3.40-25.0%-3.85-28.2%-3.50-25.7%
Usd Book Value Change Per Share-9.22-67.7%5.6841.7%-4.01-29.4%-0.85-6.2%0.251.9%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.010.0%0.000.0%
Usd Total Gains Per Share-9.22-67.7%5.6841.7%-4.01-29.4%-0.84-6.2%0.261.9%
Usd Price Per Share9.10-2.83-2.40-3.05-2.61-
Price to Earnings Ratio-0.22--0.07-0.54-0.04--0.04-
Price-to-Total Gains Ratio-0.99--0.27-1.69-2.74-0.99-
Price to Book Ratio1.00-0.19--3.87--0.24-0.16-
Price-to-Total Gains Ratio-0.99--0.27-1.69-2.74-0.99-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share13.62
Number of shares73
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.01
Usd Book Value Change Per Share5.68-0.85
Usd Total Gains Per Share5.68-0.84
Gains per Quarter (73 shares)414.76-61.45
Gains per Year (73 shares)1,659.03-245.80
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10165916492-248-256
20331833084-496-502
30497749676-743-748
40663666268-991-994
508295828510-1239-1240
609954994412-1487-1486
70116131160314-1735-1732
80132721326216-1982-1978
90149311492118-2230-2224
100165901658020-2478-2470

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%1.011.00.08.3%2.018.00.010.0%3.033.00.08.3%3.033.00.08.3%
Book Value Change Per Share2.02.00.050.0%5.07.00.041.7%9.011.00.045.0%14.022.00.038.9%14.022.00.038.9%
Dividend per Share0.00.04.00.0%0.00.012.00.0%2.00.018.010.0%2.00.034.05.6%2.00.034.05.6%
Total Gains per Share2.02.00.050.0%5.07.00.041.7%9.011.00.045.0%14.022.00.038.9%14.022.00.038.9%

Fundamentals of Avalo Therapeutics Inc

About Avalo Therapeutics Inc

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation. The company's drug candidates include AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as Crohn's disease; Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome; and AVTX-008, a fully human B and T Lymphocyte Attenuator (BTLA) agonist fusion protein. It also develops AVTX-803, a L-fucose monosaccharide therapy for treatment of Leukocyte Adhesion Deficiency Type II. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

Fundamental data was last updated by Penke on 2024-04-11 16:43:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just able to pay all its short-term debts.
The company is just able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Avalo Therapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Avalo Therapeutics Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Avalo Therapeutics Inc to the Biotechnology industry mean.
  • A Net Profit Margin of -1,430.5% means that $-14.30 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Avalo Therapeutics Inc:

  • The MRQ is -1,430.5%. The company is making a huge loss. -2
  • The TTM is -1,753.9%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-1,430.5%TTM-1,753.9%+323.5%
TTM-1,753.9%YOY-1,052.7%-701.2%
TTM-1,753.9%5Y-1,633.0%-120.9%
5Y-1,633.0%10Y-1,071.6%-561.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1,430.5%-197.2%-1,233.3%
TTM-1,753.9%-210.4%-1,543.5%
YOY-1,052.7%-279.3%-773.4%
5Y-1,633.0%-436.8%-1,196.2%
10Y-1,071.6%-599.3%-472.3%
1.1.2. Return on Assets

Shows how efficient Avalo Therapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Avalo Therapeutics Inc to the Biotechnology industry mean.
  • -38.9% Return on Assets means that Avalo Therapeutics Inc generated $-0.39 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Avalo Therapeutics Inc:

  • The MRQ is -38.9%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -29.5%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-38.9%TTM-29.5%-9.4%
TTM-29.5%YOY-24.1%-5.4%
TTM-29.5%5Y-24.0%-5.5%
5Y-24.0%10Y-23.2%-0.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-38.9%-13.6%-25.3%
TTM-29.5%-12.9%-16.6%
YOY-24.1%-11.9%-12.2%
5Y-24.0%-14.2%-9.8%
10Y-23.2%-16.2%-7.0%
1.1.3. Return on Equity

Shows how efficient Avalo Therapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Avalo Therapeutics Inc to the Biotechnology industry mean.
  • -111.8% Return on Equity means Avalo Therapeutics Inc generated $-1.12 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Avalo Therapeutics Inc:

  • The MRQ is -111.8%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -36.9%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-111.8%TTM-36.9%-75.0%
TTM-36.9%YOY-86.9%+50.1%
TTM-36.9%5Y-54.1%+17.3%
5Y-54.1%10Y-90.1%+35.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-111.8%-17.0%-94.8%
TTM-36.9%-16.1%-20.8%
YOY-86.9%-15.4%-71.5%
5Y-54.1%-20.0%-34.1%
10Y-90.1%-21.1%-69.0%

1.2. Operating Efficiency of Avalo Therapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Avalo Therapeutics Inc is operating .

  • Measures how much profit Avalo Therapeutics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Avalo Therapeutics Inc to the Biotechnology industry mean.
  • An Operating Margin of -695.6% means the company generated $-6.96  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Avalo Therapeutics Inc:

  • The MRQ is -695.6%. The company is operating very inefficient. -2
  • The TTM is -1,316.2%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-695.6%TTM-1,316.2%+620.6%
TTM-1,316.2%YOY-972.4%-343.8%
TTM-1,316.2%5Y-1,419.7%+103.5%
5Y-1,419.7%10Y-925.9%-493.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-695.6%-286.1%-409.5%
TTM-1,316.2%-224.4%-1,091.8%
YOY-972.4%-288.4%-684.0%
5Y-1,419.7%-475.2%-944.5%
10Y-925.9%-624.7%-301.2%
1.2.2. Operating Ratio

Measures how efficient Avalo Therapeutics Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 7.49 means that the operating costs are $7.49 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Avalo Therapeutics Inc:

  • The MRQ is 7.494. The company is inefficient in keeping operating costs low. -1
  • The TTM is 14.003. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ7.494TTM14.003-6.509
TTM14.003YOY10.709+3.294
TTM14.0035Y15.589-1.585
5Y15.58910Y18.011-2.422
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ7.4942.997+4.497
TTM14.0033.247+10.756
YOY10.7093.766+6.943
5Y15.5895.675+9.914
10Y18.0117.857+10.154

1.3. Liquidity of Avalo Therapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Avalo Therapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 1.82 means the company has $1.82 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Avalo Therapeutics Inc:

  • The MRQ is 1.818. The company is able to pay all its short-term debts. +1
  • The TTM is 1.272. The company is just able to pay all its short-term debts.
Trends
Current periodCompared to+/- 
MRQ1.818TTM1.272+0.546
TTM1.272YOY1.307-0.035
TTM1.2725Y1.729-0.456
5Y1.72910Y1.806-0.077
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.8183.930-2.112
TTM1.2724.251-2.979
YOY1.3075.436-4.129
5Y1.7296.045-4.316
10Y1.8066.363-4.557
1.3.2. Quick Ratio

Measures if Avalo Therapeutics Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Avalo Therapeutics Inc to the Biotechnology industry mean.
  • A Quick Ratio of 1.64 means the company can pay off $1.64 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Avalo Therapeutics Inc:

  • The MRQ is 1.635. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 1.156. The company is just able to pay all its short-term debts with the most liquid assets.
Trends
Current periodCompared to+/- 
MRQ1.635TTM1.156+0.479
TTM1.156YOY1.206-0.050
TTM1.1565Y1.706-0.550
5Y1.70610Y1.718-0.012
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.6353.629-1.994
TTM1.1564.065-2.909
YOY1.2065.397-4.191
5Y1.7065.993-4.287
10Y1.7186.277-4.559

1.4. Solvency of Avalo Therapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Avalo Therapeutics Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Avalo Therapeutics Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.65 means that Avalo Therapeutics Inc assets are financed with 65.2% credit (debt) and the remaining percentage (100% - 65.2%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Avalo Therapeutics Inc:

  • The MRQ is 0.652. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.903. The company is just able to pay all its debts by selling its assets.
Trends
Current periodCompared to+/- 
MRQ0.652TTM0.903-0.251
TTM0.903YOY1.116-0.214
TTM0.9035Y0.724+0.179
5Y0.72410Y1.050-0.326
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6520.332+0.320
TTM0.9030.334+0.569
YOY1.1160.268+0.848
5Y0.7240.366+0.358
10Y1.0500.390+0.660
1.4.2. Debt to Equity Ratio

Measures if Avalo Therapeutics Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Avalo Therapeutics Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 187.4% means that company has $1.87 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Avalo Therapeutics Inc:

  • The MRQ is 1.874. The company is just able to pay all its debts with equity.
  • The TTM is 0.717. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ1.874TTM0.717+1.158
TTM0.717YOY2.190-1.473
TTM0.7175Y1.411-0.694
5Y1.41110Y2.282-0.871
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.8740.381+1.493
TTM0.7170.390+0.327
YOY2.1900.334+1.856
5Y1.4110.434+0.977
10Y2.2820.466+1.816

2. Market Valuation of Avalo Therapeutics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Avalo Therapeutics Inc generates.

  • Above 15 is considered overpriced but always compare Avalo Therapeutics Inc to the Biotechnology industry mean.
  • A PE ratio of -0.22 means the investor is paying $-0.22 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Avalo Therapeutics Inc:

  • The EOD is -0.334. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.223. Based on the earnings, the company is expensive. -2
  • The TTM is -0.068. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.334MRQ-0.223-0.111
MRQ-0.223TTM-0.068-0.155
TTM-0.068YOY0.539-0.607
TTM-0.0685Y0.045-0.113
5Y0.04510Y-0.042+0.087
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.334-2.315+1.981
MRQ-0.223-2.560+2.337
TTM-0.068-2.664+2.596
YOY0.539-4.122+4.661
5Y0.045-6.258+6.303
10Y-0.042-6.108+6.066
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Avalo Therapeutics Inc:

  • The EOD is -0.934. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.624. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.167. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.934MRQ-0.624-0.310
MRQ-0.624TTM-0.167-0.457
TTM-0.167YOY0.230-0.397
TTM-0.1675Y-0.502+0.335
5Y-0.50210Y-0.735+0.233
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.934-3.067+2.133
MRQ-0.624-3.251+2.627
TTM-0.167-3.545+3.378
YOY0.230-5.595+5.825
5Y-0.502-8.315+7.813
10Y-0.735-8.708+7.973
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Avalo Therapeutics Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.00 means the investor is paying $1.00 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Avalo Therapeutics Inc:

  • The EOD is 1.495. Based on the equity, the company is underpriced. +1
  • The MRQ is 0.999. Based on the equity, the company is cheap. +2
  • The TTM is 0.185. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD1.495MRQ0.999+0.496
MRQ0.999TTM0.185+0.814
TTM0.185YOY-3.874+4.059
TTM0.1855Y-0.242+0.427
5Y-0.24210Y0.164-0.406
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.4951.905-0.410
MRQ0.9992.111-1.112
TTM0.1852.095-1.910
YOY-3.8742.836-6.710
5Y-0.2423.443-3.685
10Y0.1643.794-3.630
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Avalo Therapeutics Inc.

3.1. Institutions holding Avalo Therapeutics Inc

Institutions are holding 8.119% of the shares of Avalo Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31BlackRock Inc1.9805015876154403541.2844
2023-12-31Natixis SA0.57430.0003460446040
2023-12-31Tower Research Capital LLC0.22030.000217661559753.1401
2023-12-31FNY Investment Advisers, LLC0.06510.00445225220
2023-12-31Royal Bank of Canada0.017201381380
2023-12-31Morgan Stanley - Brokerage Accounts0.005504400
2023-09-30Newbridge Financial Services Group, Inc.001000
2023-12-31Wells Fargo & Co0.00108360
2023-12-31UBS Group AG0.00020220
2023-12-31Group One Trading, LP0.0002021100
2023-12-31JPMorgan Chase & Co0.00020220
2023-12-31First Horizon Advisors Inc.0.00010100
2023-12-31Advisor Group Holdings, Inc.0.00010100
2023-12-31State Street Corporation000-107-100
2023-12-31Mariner Wealth Advisors, LLC000-77-100
2023-12-31Susquehanna International Group, LLP000-94-100
2023-12-31Acadian Asset Management LLC000-1179-100
2023-12-31JANE STREET GROUP, LLC000-114-100
2023-09-30VR Adviser, LLC000-1250000-100
2023-12-31Northern Trust Corp000-45-100
Total 2.86470.004922976-1229345-5,350.6%

3.2. Funds holding Avalo Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-09-30BlackRock Extended Mkt Composite0.006501344500
2024-02-29Fidelity Extended Market Index0.52160.0001449900
2024-03-28iShares Micro-Cap ETF0.20490.0042176700
2024-02-29Fidelity Series Total Market Index0.11960103200
2024-02-29Fidelity Nasdaq Composite Index0.0879075800
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr0.035030200
2024-02-29Fidelity Total Market Index0.007306300
2023-11-30Guggenheim Active Allocation Fund003000
2023-12-31NT Ext Equity Mkt Idx Fd - L0.002201900
2023-12-31Northern Trust Extended Eq Market Idx0.002201900
2023-12-31NT Ext Equity Mkt Idx Fd - NL0.002201900
2024-03-31BlackRock U.S. Equity Market F0.002017213.3333
2023-12-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.001701500
2024-02-29Spartan Total Market Index Pool E0.001501300
2024-03-31State St US Extended Mkt Indx NL Cl C0.001401200
2023-12-31SSgA U.S. Extended Market Index Class I0.0013011-1-8.3333
2024-02-291290 VT Micro Cap K0.00090800
2024-02-29Spartan Extended Market Index Pool E0.00060500
2024-02-29State St US Ttl Mkt Indx SL Cl I0.00050400
2023-12-31SSgA U.S. Total Market Index Strategy0.00030300
Total 0.99960.004322041+1+0.0%

3.3. Insider Transactions

Insiders are holding 0.12% of the shares of Avalo Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-06-26Armistice Capital, LlcSELL11442146.4
2023-06-20Caissa Capital Management Ltd.BUY8993.6
2023-06-16Caissa Capital Management Ltd.BUY12936
2023-06-14Caissa Capital Management Ltd.BUY25835.2
2023-06-12Caissa Capital Management Ltd.BUY81041.6
2023-06-09Christopher Ryan SullivanBUY2820.8
2023-06-09Garry Arthur NeilBUY16820.8
2023-05-30Caissa Capital Management Ltd.BUY2688.8
2023-05-25Caissa Capital Management Ltd.BUY8664.8
2023-05-22Caissa Capital Management Ltd.BUY29801.6
2023-05-18Caissa Capital Management Ltd.BUY54789.6
2023-05-15Caissa Capital Management Ltd.BUY7612
2023-05-12Caissa Capital Management Ltd.BUY9588
2023-05-08Caissa Capital Management Ltd.BUY20628.8
2023-05-04Caissa Capital Management Ltd.BUY62669.6
2023-04-26Caissa Capital Management Ltd.BUY1712.8
2023-04-24Caissa Capital Management Ltd.BUY52734.4
2023-04-20Caissa Capital Management Ltd.BUY20739.2
2023-04-17Caissa Capital Management Ltd.BUY62710.4

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Avalo Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---9.2225.682-262%-4.011-57%-0.849-91%0.253-3744%
Book Value Per Share--9.1102.733+233%-3.447+138%2.542+258%1.085+740%
Current Ratio--1.8181.272+43%1.307+39%1.729+5%1.806+1%
Debt To Asset Ratio--0.6520.903-28%1.116-42%0.724-10%1.050-38%
Debt To Equity Ratio--1.8740.717+162%2.190-14%1.411+33%2.282-18%
Dividend Per Share----0%-0%0.007-100%0.004-100%
Eps---10.188-9.837-3%-3.402-67%-3.846-62%-3.504-66%
Free Cash Flow Per Share---3.647-9.617+164%-1.856-49%-3.232-11%-3.429-6%
Free Cash Flow To Equity Per Share---3.646-1.807-50%-2.614-28%-0.647-82%-1.013-72%
Gross Profit Margin--1.0011.0010%1.022-2%0.875+14%9.701-90%
Intrinsic Value_10Y_max---241.051--------
Intrinsic Value_10Y_min---206.637--------
Intrinsic Value_1Y_max---18.942--------
Intrinsic Value_1Y_min---18.602--------
Intrinsic Value_3Y_max---60.885--------
Intrinsic Value_3Y_min---58.046--------
Intrinsic Value_5Y_max---107.619--------
Intrinsic Value_5Y_min---99.547--------
Market Cap10917941.820+33%7295888.6002270048.631+221%11701297.104-38%14991219.901-51%9778431.123-25%
Net Profit Margin---14.305-17.539+23%-10.527-26%-16.330+14%-10.716-25%
Operating Margin---6.956-13.162+89%-9.724+40%-14.197+104%-9.259+33%
Operating Ratio--7.49414.003-46%10.709-30%15.589-52%18.011-58%
Pb Ratio1.495+33%0.9990.185+439%-3.874+488%-0.242+124%0.164+508%
Pe Ratio-0.334-50%-0.223-0.068-70%0.539-141%0.045-597%-0.042-81%
Price Per Share13.620+33%9.1002.831+221%2.396+280%3.052+198%2.613+248%
Price To Free Cash Flow Ratio-0.934-50%-0.624-0.167-73%0.230-371%-0.502-20%-0.735+18%
Price To Total Gains Ratio-1.477-50%-0.987-0.272-72%1.695-158%2.742-136%0.989-200%
Quick Ratio--1.6351.156+41%1.206+36%1.706-4%1.718-5%
Return On Assets---0.389-0.295-24%-0.241-38%-0.240-38%-0.232-40%
Return On Equity---1.118-0.369-67%-0.869-22%-0.541-52%-0.901-19%
Total Gains Per Share---9.2225.682-262%-4.011-57%-0.842-91%0.257-3690%
Usd Book Value--7304000.0002190750.000+233%-3137750.000+143%16683757.550-56%10647388.611-31%
Usd Book Value Change Per Share---9.2225.682-262%-4.011-57%-0.849-91%0.253-3744%
Usd Book Value Per Share--9.1102.733+233%-3.447+138%2.542+258%1.085+740%
Usd Dividend Per Share----0%-0%0.007-100%0.004-100%
Usd Eps---10.188-9.837-3%-3.402-67%-3.846-62%-3.504-66%
Usd Free Cash Flow---2924000.000-7709500.000+164%-6725500.000+130%-9437185.200+223%-6343430.389+117%
Usd Free Cash Flow Per Share---3.647-9.617+164%-1.856-49%-3.232-11%-3.429-6%
Usd Free Cash Flow To Equity Per Share---3.646-1.807-50%-2.614-28%-0.647-82%-1.013-72%
Usd Market Cap10917941.820+33%7295888.6002270048.631+221%11701297.104-38%14991219.901-51%9778431.123-25%
Usd Price Per Share13.620+33%9.1002.831+221%2.396+280%3.052+198%2.613+248%
Usd Profit---8167999.000-7885999.750-3%-10414500.000+28%-11857515.900+45%-8081532.222-1%
Usd Revenue--571000.000481250.000+19%4512750.000-87%1941098.300-71%2267586.528-75%
Usd Total Gains Per Share---9.2225.682-262%-4.011-57%-0.842-91%0.257-3690%
 EOD+5 -3MRQTTM+18 -16YOY+14 -205Y+13 -2310Y+10 -26

4.2. Fundamental Score

Let's check the fundamental score of Avalo Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.334
Price to Book Ratio (EOD)Between0-11.495
Net Profit Margin (MRQ)Greater than0-14.305
Operating Margin (MRQ)Greater than0-6.956
Quick Ratio (MRQ)Greater than11.635
Current Ratio (MRQ)Greater than11.818
Debt to Asset Ratio (MRQ)Less than10.652
Debt to Equity Ratio (MRQ)Less than11.874
Return on Equity (MRQ)Greater than0.15-1.118
Return on Assets (MRQ)Greater than0.05-0.389
Total3/10 (30.0%)

4.3. Technical Score

Let's check the technical score of Avalo Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5055.639
Ma 20Greater thanMa 5012.558
Ma 50Greater thanMa 1007.850
Ma 100Greater thanMa 2009.057
OpenGreater thanClose15.620
Total3/5 (60.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Tax Provision  808-1718-17-9
Net Interest Income  -9490-949-47-996-557-1,5531,63481
Income Tax Expense  808-1718-17-9
Cost of Revenue  620-69551157708-461247-468-221



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets20,993
Total Liabilities13,689
Total Stockholder Equity7,304
 As reported
Total Liabilities 13,689
Total Stockholder Equity+ 7,304
Total Assets = 20,993

Assets

Total Assets20,993
Total Current Assets8,395
Long-term Assets12,598
Total Current Assets
Cash And Cash Equivalents 7,416
Net Receivables 136
Other Current Assets 843
Total Current Assets  (as reported)8,395
Total Current Assets  (calculated)8,395
+/-0
Long-term Assets
Property Plant Equipment 1,965
Goodwill 10,502
Long-term Assets Other 131
Long-term Assets  (as reported)12,598
Long-term Assets  (calculated)12,598
+/- 0

Liabilities & Shareholders' Equity

Total Current Liabilities4,618
Long-term Liabilities9,071
Total Stockholder Equity7,304
Total Current Liabilities
Short-term Debt 537
Accounts payable 446
Other Current Liabilities 3,635
Total Current Liabilities  (as reported)4,618
Total Current Liabilities  (calculated)4,618
+/-0
Long-term Liabilities
Capital Lease Obligations 537
Long-term Liabilities Other 3,366
Long-term Liabilities  (as reported)9,071
Long-term Liabilities  (calculated)3,903
+/- 5,168
Total Stockholder Equity
Common Stock1
Retained Earnings -335,134
Other Stockholders Equity 342,437
Total Stockholder Equity (as reported)7,304
Total Stockholder Equity (calculated)7,304
+/-0
Other
Capital Stock1
Cash and Short Term Investments 7,416
Common Stock Shares Outstanding 802
Liabilities and Stockholders Equity 20,993
Net Debt -3,513
Net Invested Capital 7,304
Net Working Capital 3,777
Property Plant and Equipment Gross 2,507
Short Long Term Debt Total 3,903



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-31
> Total Assets 
0
0
0
12,317
9,170
7,582
5,451
21,658
16,929
13,172
9,583
5,769
3,561
6,048
28,204
43,124
62,145
67,612
70,251
74,870
59,621
57,194
36,109
44,120
69,205
59,187
43,755
63,345
64,085
95,356
80,214
61,899
32,224
36,547
33,367
36,235
24,235
29,270
20,993
20,99329,27024,23536,23533,36736,54732,22461,89980,21495,35664,08563,34543,75559,18769,20544,12036,10957,19459,62174,87070,25167,61262,14543,12428,2046,0483,5615,7699,58313,17216,92921,6585,4517,5829,17012,317000
   > Total Current Assets 
0
0
0
12,161
9,004
6,306
3,413
21,623
16,892
13,131
9,492
5,663
3,459
5,952
28,107
10,991
11,838
18,473
21,932
26,744
13,899
12,589
17,724
25,485
50,245
41,033
26,005
46,096
47,364
77,006
61,845
43,659
15,021
19,450
16,416
19,253
7,519
12,659
8,395
8,39512,6597,51919,25316,41619,45015,02143,65961,84577,00647,36446,09626,00541,03350,24525,48517,72412,58913,89926,74421,93218,47311,83810,99128,1075,9523,4595,6639,49213,13116,89221,6233,4136,3069,00412,161000
       Cash And Cash Equivalents 
0
0
0
11,742
8,599
6,143
3,308
21,162
16,602
11,880
8,815
5,128
3,002
5,461
23,955
2,472
2,180
6,838
10,646
16,121
9,387
5,251
3,609
5,659
45,391
33,391
18,919
38,292
40,435
71,506
54,585
38,469
11,249
16,943
13,172
16,687
6,307
10,180
7,416
7,41610,1806,30716,68713,17216,94311,24938,46954,58571,50640,43538,29218,91933,39145,3915,6593,6095,2519,38716,12110,6466,8382,1802,47223,9555,4613,0025,1288,81511,88016,60221,1623,3086,1438,59911,742000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7,629
14,709
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000014,7097,6290000000000000000000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
650
379
133
187
75
30
3,679
3,396
9,273
8,627
8,249
3,003
5,164
5,242
4,259
3,985
5,957
4,385
5,186
5,118
3,912
4,799
2,383
1,850
1,314
1,919
857
44
1,538
136
1361,538448571,9191,3141,8502,3834,7993,9125,1185,1864,3855,9573,9854,2595,2425,1643,0038,2498,6279,2733,3963,6793075187133379650000000000
       Other Current Assets 
0
0
0
360
346
104
105
402
232
542
210
391
250
402
341
703
954
1,260
1,530
1,248
865
1,670
707
777
824
1,544
2,660
2,465
1,750
1,408
2,372
2,682
1,885
1,118
1,290
1,627
1,135
940
843
8439401,1351,6271,2901,1181,8852,6822,3721,4081,7502,4652,6601,5448247777071,6708651,2481,5301,260954703341402250391210542232402105104346360000
   > Long-term Assets 
0
0
0
156
166
1,277
2,038
35
37
41
90
106
102
96
97
32,133
50,307
49,139
48,319
48,126
45,722
44,605
18,385
18,634
18,960
18,154
17,750
17,249
16,721
18,350
18,369
18,240
17,203
17,097
16,951
16,982
16,716
16,611
12,598
12,59816,61116,71616,98216,95117,09717,20318,24018,36918,35016,72117,24917,75018,15418,96018,63418,38544,60545,72248,12648,31949,13950,30732,1339796102106904137352,0381,277166156000
       Property Plant Equipment 
0
0
0
39
33
28
41
35
37
41
40
43
39
33
34
45
58
92
587
1,477
1,526
1,496
1,448
1,417
1,741
1,708
1,607
1,530
1,431
1,410
2,695
2,604
2,567
2,507
2,411
2,442
2,176
2,071
1,965
1,9652,0712,1762,4422,4112,5072,5672,6042,6951,4101,4311,5301,6071,7081,7411,4171,4481,4961,5261,477587925845343339434041373541283339000
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
14,292
18,070
16,411
16,411
16,411
16,411
16,411
14,409
14,409
14,409
14,409
14,409
14,409
14,409
14,409
14,409
14,409
14,409
14,409
14,409
14,409
14,409
14,409
10,502
10,50214,40914,40914,40914,40914,40914,40914,40914,40914,40914,40914,40914,40914,40914,40914,40914,40916,41116,41116,41116,41116,41118,07014,292000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
17,664
32,003
32,456
31,239
30,161
27,633
26,595
2,426
2,696
2,292
1,889
1,585
1,161
732
304
38
0
0
0
0
0
0
0
0
00000000383047321,1611,5851,8892,2922,6962,42626,59527,63330,16131,23932,45632,00317,664000000000000000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
149
149
149
149
2,227
1,227
1,227
227
181
131
0
131
0
0
0013101311812271,2271,2272,2271491491491490000000000000000000000000
> Total Liabilities 
0
0
0
38,648
38,688
9,906
38,302
8,574
8,048
7,601
8,996
5,562
3,987
2,912
6,083
15,264
42,926
48,104
49,343
51,750
41,925
38,973
15,113
18,531
18,627
20,620
19,194
30,190
42,497
55,047
57,132
55,556
38,175
38,575
44,282
42,502
31,204
14,575
13,689
13,68914,57531,20442,50244,28238,57538,17555,55657,13255,04742,49730,19019,19420,62018,62718,53115,11338,97341,92551,75049,34348,10442,92615,2646,0832,9123,9875,5628,9967,6018,0488,57438,3029,90638,68838,648000
   > Total Current Liabilities 
0
0
0
4,994
5,751
5,812
6,654
5,850
6,172
6,586
7,496
4,312
2,737
1,662
4,833
11,406
19,045
24,912
26,217
28,135
18,765
17,262
12,160
15,330
14,595
16,571
15,225
26,360
21,674
19,038
19,888
17,893
15,395
18,149
22,114
23,245
22,454
6,005
4,618
4,6186,00522,45423,24522,11418,14915,39517,89319,88819,03821,67426,36015,22516,57114,59515,33012,16017,26218,76528,13526,21724,91219,04511,4064,8331,6622,7374,3127,4966,5866,1725,8506,6545,8125,7514,994000
       Short-term Debt 
0
0
0
1,906
2,729
3,044
3,129
3,208
3,304
3,391
3,190
2,354
1,492
608
0
788
1,050
1,050
1,050
1,050
1,050
1,050
0
0
432
449
426
357
288
219
485
522
524
2,564
6,462
9,296
14,650
536
537
53753614,6509,2966,4622,564524522485219288357426449432001,0501,0501,0501,0501,0501,05078806081,4922,3543,1903,3913,3043,2083,1293,0442,7291,906000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,564
5,930
9,296
14,115
0
0
0014,1159,2965,9302,564000000000000000000000000000000000
       Accounts payable 
0
0
0
931
722
1,247
1,952
678
591
756
809
1,010
596
327
313
1,299
2,940
1,536
1,446
1,249
1,445
826
2,078
2,726
2,558
1,927
2,574
11,913
3,965
3,568
3,369
3,757
2,164
1,447
2,882
5,565
751
789
446
4467897515,5652,8821,4472,1643,7573,3693,5683,96511,9132,5741,9272,5582,7262,0788261,4451,2491,4461,5362,9401,2993133275961,0108097565916781,9521,247722931000
       Other Current Liabilities 
0
0
0
1,182
1,717
1,522
54
78
125
35
136
6
9
7
4,521
10,107
2,922
2,546
2,236
2,276
1,567
1,364
10,083
12,604
5,664
5,921
1,452
228
103
20
9
13,614
12,707
13,696
12,682
8,273
7,588
5,216
3,635
3,6355,2167,5888,27312,68213,69612,70713,6149201032281,4525,9215,66412,60410,0831,3641,5672,2762,2362,5462,92210,1074,5217961363512578541,5221,7171,182000
   > Long-term Liabilities 
0
0
0
33,654
32,937
4,094
31,648
8,574
1,876
1,015
1,500
1,250
1,250
1,250
1,250
3,858
23,880
23,193
23,126
23,615
23,160
21,710
2,953
3,201
4,032
4,049
3,969
3,830
20,823
36,009
37,244
37,663
22,780
20,426
22,168
19,257
8,750
8,570
9,071
9,0718,5708,75019,25722,16820,42622,78037,66337,24436,00920,8233,8303,9694,0494,0323,2012,95321,71023,16023,61523,12623,19323,8803,8581,2501,2501,2501,2501,5001,0151,8768,57431,6484,09432,93733,654000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
17,143
32,483
0
0
0
0
0
10,470
0
0
0
00010,4700000032,48317,1430000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,955
2,930
2,812
2,682
3,526
4,411
2,535
4,067
3,924
6,971
0
8,750
0
0
008,75006,9713,9244,0672,5354,4113,5262,6822,8122,9302,9550000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
90
111
122
130
0
0
0
0
0
5,158
0
0
0
0005,158000001301221119000000000000000000000000000
> Total Stockholder Equity
0
0
0
-26,331
-29,518
-2,324
-32,851
13,084
8,881
5,571
587
207
-426
3,135
22,120
27,860
19,219
19,508
20,908
23,121
17,696
18,221
20,996
25,589
50,578
38,567
24,562
33,155
21,588
40,309
23,082
6,343
-5,951
-2,028
-10,915
-6,267
-6,969
14,695
7,304
7,30414,695-6,969-6,267-10,915-2,028-5,9516,34323,08240,30921,58833,15524,56238,56750,57825,58920,99618,22117,69623,12120,90819,50819,21927,86022,1203,135-4262075875,5718,88113,084-32,851-2,324-29,518-26,331000
   Common Stock
0
0
0
1
18
5
1
9
9
9
9
9
11
14
26
2,687
34
41
41
43
43
44
44
60
75
75
75
89
96
112
113
113
9
9
9
13
14
192
1
11921413999113113112968975757560444443434141342,6872614119999915181000
   Retained Earnings Total Equity000-313,77900000-242,970-225,575-208,470-177,79000000000000000000000000000
   Accumulated Other Comprehensive Income 000000000000000000000000000000000000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
202,276
241,535
247,067
283,167
0
0
0
0
0
307,499
0
0
0
000307,49900000283,167247,067241,535202,27600000000000000000000000000
   Treasury Stock000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
16,742
16,775
46,895
-11,282
66,639
67,576
67,790
68,974
70,233
71,559
76,916
77,168
83,338
87,241
112,126
119,082
128,747
129,546
134,086
135,239
160,936
199,191
200,639
202,276
241,535
247,067
283,167
285,135
290,447
291,244
291,975
292,900
307,499
314,755
341,469
342,437
342,437341,469314,755307,499292,900291,975291,244290,447285,135283,167247,067241,535202,276200,639199,191160,936135,239134,086129,546128,747119,082112,12687,24183,33877,16876,91671,55970,23368,97467,79067,57666,639-11,28246,89516,77516,742000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue1,924
Cost of Revenue-1,284
Gross Profit640640
 
Operating Income (+$)
Gross Profit640
Operating Expense-24,084
Operating Income-23,444-23,444
 
Operating Expense (+$)
Research Development13,784
Selling General Administrative10,267
Selling And Marketing Expenses33
Operating Expense24,08424,084
 
Net Interest Income (+$)
Interest Income0
Interest Expense-3,417
Other Finance Cost-1,030
Net Interest Income-4,447
 
Pretax Income (+$)
Operating Income-23,444
Net Interest Income-4,447
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-31,530-15,358
EBIT - interestExpense = -26,861
-31,530
-28,127
Interest Expense3,417
Earnings Before Interest and Taxes (EBIT)-23,444-28,113
Earnings Before Interest and Taxes (EBITDA)-23,286
 
After tax Income (+$)
Income Before Tax-31,530
Tax Provision-31
Net Income From Continuing Ops-33,188-31,561
Net Income-31,544
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses25,368
Total Other Income/Expenses Net-8,0864,447
 

Technical Analysis of Avalo Therapeutics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Avalo Therapeutics Inc. The general trend of Avalo Therapeutics Inc is NEUTRAL with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Avalo Therapeutics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (0.0%) Bearish trend (0.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Avalo Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 19.34 < 22.08 < 22.68.

The bearish price targets are: 11.10 > 6.1799 > 4.35.

Tweet this
Avalo Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Avalo Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 7/14.
The longshort score for the Moving Averages is 0/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Avalo Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Avalo Therapeutics Inc. The current macd is 2.32191005.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Avalo Therapeutics Inc price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Avalo Therapeutics Inc. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Avalo Therapeutics Inc price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Avalo Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartAvalo Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Avalo Therapeutics Inc. The current adx is 44.20.

The long score for the Directional Movement Index (DMI) is 3/7.
The longshort score for the Directional Movement Index (DMI) is 3/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Avalo Therapeutics Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bullish trend. The ADX is declining, the bullish trend is weakening. Could be a potential reversal to the downside. +2
Avalo Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Avalo Therapeutics Inc. The current sar is 11.03.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Avalo Therapeutics Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Avalo Therapeutics Inc. The current rsi is 55.64. The current phase is Correction in bear market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 2/(-13 +13).

  • Correction in bear market: Extended price decline in a downtrend, significant pullback. Consider reducing exposure, wait for signs of trend reversal.
  • Trending down: The RSI is trending down. -1
Avalo Therapeutics Inc Daily Relative Strength Index (RSI) ChartAvalo Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Avalo Therapeutics Inc. The current phase is Oversold in neutral market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Avalo Therapeutics Inc price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Avalo Therapeutics Inc Daily Stochastic Oscillator ChartAvalo Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Avalo Therapeutics Inc. The current cci is 18.89.

Avalo Therapeutics Inc Daily Commodity Channel Index (CCI) ChartAvalo Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Avalo Therapeutics Inc. The current cmo is 2.3357274.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Avalo Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartAvalo Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Avalo Therapeutics Inc. The current willr is -89.21232877.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Avalo Therapeutics Inc Daily Williams %R ChartAvalo Therapeutics Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Avalo Therapeutics Inc.

Avalo Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Avalo Therapeutics Inc. The current atr is 2.72974542.

Avalo Therapeutics Inc Daily Average True Range (ATR) ChartAvalo Therapeutics Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Avalo Therapeutics Inc. The current obv is 34,499,895.

Avalo Therapeutics Inc Daily On-Balance Volume (OBV) ChartAvalo Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Avalo Therapeutics Inc. The current mfi is 92.48.

The long score for the Money Flow Index (MFI) is 2/2.
The longshort score for the Money Flow Index (MFI) is 2/(-2 +2).

  • MFI > 50: +1
  • MFI > 80: +1
Avalo Therapeutics Inc Daily Money Flow Index (MFI) ChartAvalo Therapeutics Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Avalo Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-24STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-28DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-11-30MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-01STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-06RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-07STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-12STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-13DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2023-12-14MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-12-19CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-20WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-21DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-26STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-27DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-12-29CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-05MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-11CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-19MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-22MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-23MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-26RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-29MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-30MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-08SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-13CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-14CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-15STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-20SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-27CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-04STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-08STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-11MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-12MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-14CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-26STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-28SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-01ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-02RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside

6.3. Candlestick Patterns

Avalo Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Avalo Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5055.639
Ma 20Greater thanMa 5012.558
Ma 50Greater thanMa 1007.850
Ma 100Greater thanMa 2009.057
OpenGreater thanClose15.620
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Avalo Therapeutics Inc with someone you think should read this too:
  • Are you bullish or bearish on Avalo Therapeutics Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Avalo Therapeutics Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Avalo Therapeutics Inc

I send you an email if I find something interesting about Avalo Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Avalo Therapeutics Inc.

Receive notifications about Avalo Therapeutics Inc in your mailbox!